Pfizer, UCB, UK create tech company to speed R&D

Pfizer and UCB have joined forces to launch Cyclofluidic, which they describe as a "breakthrough technology company established with the aim of significantly accelerating the drug discovery process by allowing researchers to test a greater range of potential new medicines in a shorter time."

The new tech company--which is also being supported by the UK government's Technology Strategy Board--says it will focus on flow chemistry and flow biology.

"Cyclofluidic's entry into the rapidly evolving microfluidic technology area has the potential to radically transform the medicinal chemistry and biology interface," says Dr Neil Weir, senior vice president research at UCB. "It's an exciting opportunity for UCB and Pfizer to collaborate and offers real potential for improved productivity, underlining our commitment to innovation for patients."

- check out the joint release

Related Articles:
UC center wants efficient biotech drug production
Efficient drug programs demand partners, outsourcing
Can Big Pharma effectively develop new drugs?